Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.75% -0.11% 8.590B 2.712M
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0% 50.00% 7.088B Upgrade

Basic Info

Investment Strategy
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name ARK ETF Trust
Prospectus Benchmark Index
NASDAQ Health Care GR EUR 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Catherine Wood 6.67 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 1
7.088B
-4.645B Category Low
7.088B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of July 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of August 03, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
-1.25%
-19.26%
46.60%
-0.11%
44.06%
180.6%
-9.08%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
15.94%
47.55%
10.90%
-19.59%
37.07%
-0.30%
19.74%
12.96%
1.77%
--
--
--
--
--
--
51.52%
-2.58%
--
--
--
--
--
--
54.29%
11.31%
--
--
--
--
--
--
--
--
As of August 03, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (8-4-21) 0%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of July 29, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of July 29, 2021

Asset Allocation

As of July 29, 2021.
Type % Net % Long % Short
Cash 0.15% Upgrade Upgrade
Stock 99.85% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Teladoc Health Inc 7.23% 150.36 -0.69%
Pacific Biosciences of California Inc 5.25% 29.22 -3.28%
Exact Sciences Corp 5.03% 105.04 0.80%
Regeneron Pharmaceuticals Inc 4.62% 585.47 -0.18%
Vertex Pharmaceuticals Inc 4.21% 200.00 -0.02%
Fate Therapeutics Inc 4.15% 83.30 0.06%
Ionis Pharmaceuticals Inc 3.83% 37.91 0.26%
CareDx Inc 3.74% 82.01 -0.29%
Twist Bioscience Corp 3.40% 117.86 -0.97%
Veeva Systems Inc Class A 3.14% 338.88 0.25%

Basic Info

Investment Strategy
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name ARK ETF Trust
Prospectus Benchmark Index
NASDAQ Health Care GR EUR 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Catherine Wood 6.67 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (8-4-21) 0%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of July 29, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of July 29, 2021

Fund Details

Key Dates
Inception Date 10/30/2014
Last Annual Report Date 7/31/2020
Last Prospectus Date 11/30/2020
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No